Shares of GE HealthCare surged +6.2% to $75.53 after the medical-technology company reported third-quarter results that cleared Wall Street's bar on both revenue and earnings, then sweetened its full-year forecast. Revenue rose 7.2% year over year to $5.51 billion , while adjusted EPS of $1.34 topped the consensus estimate of $1.20 by more than 11% . The beat matters because the stock is still roughly 16% below its 52-week high of $89.77, and investors needed proof that the company's profit engine is accelerating — not just holding steady.

  • The Real Story Is Margins, Not Just Sales. This was a profitability-led beat rather than a broad top-line surprise.

Adjusted operating profit margin reached 16.6%, up from 14.8% a year ago — a 180-basis-point jump (meaning for every dollar of revenue, GEHC kept nearly two extra cents as operating profit). Management credited higher volume, better pricing, and tighter cost controls. If those levers hold, profit can grow faster than revenue — exactly what shareholders want.

  • A Higher Guidance Bar Signals Management Confidence. Full-year adjusted EPS guidance was raised to $4.95–$5.05, with expected organic revenue growth of roughly 4.0%.

The prior EPS range was $4.80–$5.00 , so the midpoint moved up about 2%. That's a modest but meaningful signal that the Q3 strength isn't a one-off.

  • A $23.7 Billion Backlog Offers Visibility — With a Caveat. Organic orders grew 4.0% and the backlog reached $23.7 billion , giving the company roughly a year's worth of unfilled demand. However, margin gains were partly aided by a favorable year-over-year tariff comparison , and free cash flow of $793 million included a $55 million tariff refund . Strip out that one-time item and the cash story is slightly less impressive.

  • The Stock Is Cheaper Than Peers — But the Market Wants More Proof. GEHC still sits roughly 20% below its 52-week high , and the average analyst price target of about $83 implies another ~10% upside from today's price . At least one valuation model pegs fair value near $85 . The gap between the current price and those targets suggests the Street believes in the story but wants to see margin expansion sustained for more than a single quarter before fully buying in.